<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597931</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20-7186-LT-CTIL</org_study_id>
    <nct_id>NCT04597931</nct_id>
  </id_info>
  <brief_title>Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density</brief_title>
  <official_title>Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to determine the effects of monthly romosozumab for one year or&#xD;
      one-time zoledronic acid on bone mineral density (BMD) and biochemical markers of bone&#xD;
      formation and resorption, in patients with spinal cord injury (SCI) and low BMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized open-label study to determine the effects of monthly romosozumab for 12&#xD;
      month or one-time zoledronic acid infusion on bone mineral density (BMD) and biochemical&#xD;
      markers of bone formation and resorption, in patients with spinal cord injury (SCI) and low&#xD;
      BMD.&#xD;
&#xD;
      Patients: Thirty women between 20-70 years of age with spinal cord injury and low bone mass&#xD;
      (BMD T-score lower than -2.0 in at least one location: Lumbar Spine, Femoral Neck or Total&#xD;
      Hip sites) will receive study medication.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Total hip BMD change during a one-year treatment period.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Change in Femoral neck BMD at 12 months, Bone turnover markers change over time (3, 9 and 12&#xD;
      month): C-terminal telopeptide of type I collagen (CTX), N-terminal propeptide of type I&#xD;
      procollagen (P1NP).&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Thirty women between 20-70 years of age with spinal cord injury that occurred more than 24&#xD;
      month ago and low bone mass (BMD T-score lower than -2.0 in at least one location: Lumbar&#xD;
      Spine, Femoral Neck or Total Hip sites)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total hip BMD change during a one-year treatment period</measure>
    <time_frame>one year</time_frame>
    <description>BMD change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Femoral neck BMD at 12 months</measure>
    <time_frame>one year</time_frame>
    <description>BTM change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover markers change</measure>
    <time_frame>one year</time_frame>
    <description>Bone turnover markers change over time (3, 9 and 12 month)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoporosis Fracture</condition>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>SC Romosozumab 210 mg/monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC Romosozumab 210 mg/monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Zoledronic acid 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Zoledronic acid 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>SC Romosozumab 210 mg/monthly</description>
    <arm_group_label>SC Romosozumab 210 mg/monthly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>IV Zoledronic acid 5 mg</description>
    <arm_group_label>IV Zoledronic acid 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMD T-score â‰¤ -2.0 at the lumbar spine, total hip or femoral neck&#xD;
&#xD;
          -  SCI of at least 24-month but less than 7 years duration,&#xD;
&#xD;
          -  American Spinal Injury Association (ASIA) Impairment Scale A-C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  myocardial infarction (MI) or stroke within the preceding year&#xD;
&#xD;
          -  high cardiovascular risk, 10 years Framingham score over 20 %.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liana Tripto-Shkolnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center, Tel Hashomer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liana Tripto-Shkolnik, MD</last_name>
    <phone>+972526334348</phone>
    <email>TriptoShkolnik.Liana@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noa Konvalina</last_name>
    <phone>+97235302021</phone>
    <email>endo.r@sheba.health.gov.il</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Liana Tripto Shkolnik</investigator_full_name>
    <investigator_title>Deputy Director, Division of Endocrinology, Diabetes and Metabolism</investigator_title>
  </responsible_party>
  <keyword>bone mineral density</keyword>
  <keyword>fracture</keyword>
  <keyword>romosozumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

